Patents by Inventor H. Saragovi

H. Saragovi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against prostate specific membrane antigen
    Patent number: 8629247
    Abstract: Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: January 14, 2014
    Assignee: Proscan RX Pharma Inc.
    Inventors: Serge Moffett, Dominic Melançon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
  • ANTIBODIES AGAINST PROSTATE SPECIFIC MEMBRANE ANTIGEN
    Publication number: 20120093719
    Abstract: Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.
    Type: Application
    Filed: April 14, 2010
    Publication date: April 19, 2012
    Applicant: PROSCAN RX PHARMA INC.
    Inventors: Serge Moffett, Dominic Melançon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
  • PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODIES AND ANTIGEN BINDING FRAGMENTS
    Publication number: 20110189093
    Abstract: Polypeptides, antibodies or antigen-binding fragments capable of binding to prostate specific membrane antigen (PSMA) are provided. These polypeptides, antibodies or antigen-binding fragments may be used for diagnostic and/or therapeutic purposes.
    Type: Application
    Filed: April 14, 2009
    Publication date: August 4, 2011
    Applicant: PROSCAN RX PHARMA
    Inventors: Serge Moffett, Dominic Melancon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
  • Gd2 ligands
    Publication number: 20060159652
    Abstract: The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY. GD2 ligands of the invention may for example be used to treat or diagnose diseases such as cancers in which cells express GD2, including neuroblastomas.
    Type: Application
    Filed: September 19, 2003
    Publication date: July 20, 2006
    Inventors: Martin Gagnon, H Saragovi
  • Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics
    Publication number: 20060024314
    Abstract: The present invention relates to differentiation and tumorigenicity. The present invention more particularly relates to ligands which target CEA and CEACAM6 such that the adhesion, differentiation-Inhibitory activities and tumorigenic effects of Ig superfamily members, CEA and CEACAM6, can be reduced or blocked. More particularly, the present invention relates to CEA-binding agents which reverse CEA-mediated tumorigenic effects by declustering CEA and CEACAM6. In one embodiment the invention relates to methods of reducing, preventing or reversing a CEA-mediated tumorigenic effect comprising a use of a CEA-mediated tumorigenic effect reducing CEA-declustering agent. In one embodiment, the invention relates to compositions and use thereof for reversing CEA-mediated tumorigenic effects on human cancer cells and uses thereof.
    Type: Application
    Filed: April 4, 2005
    Publication date: February 2, 2006
    Inventors: Clifford Stanners, Christian Ilantzis, Cosme Ordonez-Garcia, Maryam Taheri, Robert Screaton, Abraham Fuks, H. Saragovi
  • Compound targeted for specific cells with reduced systemic toxicity
    Publication number: 20040115209
    Abstract: The present invention relates to a compound to selectively kill or protect a target cell in a patient with reduced systemic toxicity, which comprises a compound of the formula: W-Z-X wherein, X is a toxic agent or protective agent; W is a biologically active molecule which is adapted to selectively bind the target cell directly or indirectly; and Z is a breakable linker which covalently links W and X together, wherein the linked W remains bioavailable and bioactive, whereby the breakable linker releases the toxic agent or protective agent into the cell.
    Type: Application
    Filed: June 20, 2003
    Publication date: June 17, 2004
    Inventors: Uri H. Saragovi, Veronique Guillemard
  • Nerve growth factor structural analogs and their uses
    Patent number: 6017878
    Abstract: Cyclic compounds with a 3-dimensional structure that bind at least one neurotrophin receptor (NTR) under physiologic conditions in vitro or in vivo are new. Binding to NTR at least partially mimics or inhibits NT biological activity.
    Type: Grant
    Filed: August 7, 1996
    Date of Patent: January 25, 2000
    Assignee: McGill University
    Inventors: Uri H. Saragovi, Lynne Lesauteur, Claudio A. Cuello